{"bill": {"#text": " \n", "form": {"current-chamber": {"#tail": " \n", "#text": "IN THE SENATE OF THE UNITED STATES"}, "#text": "\n", "congress": {"#tail": " ", "#text": "113th CONGRESS"}, "#tail": " \n", "legis-num": {"#tail": " \n", "#text": "S. 1239"}, "official-title": {"#tail": " \n", "#text": "To expand the research and awareness activities of the National Institute of Arthritis and Musculoskeletal and Skin Diseases and the Centers for Disease Control and Prevention with respect to scleroderma, and for other purposes."}, "session": {"#tail": " \n", "#text": "1st Session"}, "distribution-code": {"#tail": " \n", "@display": "yes", "#text": "II"}, "action": {"action-date": {"#tail": " \n", "@date": "20130627", "#text": "June 27, 2013"}, "#tail": " \n", "action-desc": {"#tail": " \n", "#text": "\n        ", "sponsor": {"#tail": " introduced the following bill; which was read twice and referred to the ", "#text": "Mrs. Gillibrand", "@name-id": "S331"}, "committee-name": {"#tail": "\n      ", "@committee-id": "SSHR00", "#text": "Committee on Health, Education, Labor, and Pensions"}}, "#text": " \n"}, "legis-type": {"#tail": " \n", "#text": "A BILL"}}, "@bill-stage": "Introduced-in-Senate", "@public-private": "public", "legis-body": {"#tail": " \n", "@style": "OLC", "section": [{"@section-type": "section-one", "#tail": "\n", "text": {"#tail": " ", "quote": {"short-title": {"#tail": "\n        ", "#text": "Scleroderma Research and Awareness Act"}, "#tail": ".", "#text": "\n          "}, "#text": "This Act may be cited as the ", "@display-inline": "no-display-inline"}, "enum": {"#tail": "\n      ", "#text": "1."}, "header": {"#tail": "\n      ", "#text": "Short title"}, "#text": "\n      ", "@id": "H94108626BE1E4AEBB01C98AD4D308BF"}, {"#tail": "\n", "text": {"#tail": " \n", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " finds as follows:", "@entity-type": "federal-body", "#text": "Congress", "@entity-id": "0001"}, "#text": "The ", "@display-inline": "no-display-inline"}, "enum": {"#tail": "\n      ", "#text": "2."}, "header": {"#tail": "\n      ", "#text": "Findings"}, "paragraph": [{"#tail": "\n", "text": {"#tail": " ", "#text": "Scleroderma is a chronic, disabling and often fatal autoimmune disease in which the body\u2019s soft tissues contract and harden due to an overproduction of collagen."}, "enum": {"#tail": "\n        ", "#text": "(1)"}, "@id": "H718B48B08D944621A8B935C4E3173188", "#text": "\n        "}, {"#tail": "\n", "text": {"#tail": " ", "#text": "Scleroderma causes damage to one or more of the body\u2019s organ systems, including the skin, heart, lungs, kidneys, gastrointestinal tract, and blood vessels."}, "enum": {"#tail": "\n        ", "#text": "(2)"}, "@id": "HEB66FE7C5C4F480ABA36647D23337500", "#text": "\n        "}, {"#tail": "\n", "text": {"#tail": " ", "#text": "It is estimated that 300,000 people in the United States suffer from scleroderma, 80 percent of whom are women often diagnosed during their child bearing years."}, "enum": {"#tail": "\n        ", "#text": "(3)"}, "@id": "HAA7838BE35CA4FE2BF901FC95CE9001E", "#text": "\n        "}, {"#tail": "\n", "text": {"#tail": " ", "#text": "Choctaw Native Americans, African-Americans, and Hispanics are disproportionately affected by scleroderma and tend to exhibit more rapidly progressing and severe cases of the disease."}, "enum": {"#tail": "\n        ", "#text": "(4)"}, "@id": "HBCD6087CF9CF4607A23E73AF60D6B98", "#text": "\n        "}, {"#tail": "\n", "text": {"#tail": " ", "#text": "The causes of scleroderma are unknown."}, "enum": {"#tail": "\n        ", "#text": "(5)"}, "@id": "H9C28CFF2375D4B829500C6C740AFA8D8", "#text": "\n        "}, {"#tail": "\n", "text": {"#tail": " ", "#text": "Scleroderma is associated with many other conditions including pulmonary hypertension, gastroparesis, Raynaud\u2019s phenomenon, Sj\u00f6gren\u2019s Syndrome and lupus."}, "enum": {"#tail": "\n        ", "#text": "(6)"}, "@id": "HB33F0CC9376042BD9EC033BE23003B11", "#text": "\n        "}, {"#tail": "\n", "text": {"#tail": " ", "#text": "The estimated total annual economic impact of scleroderma in the United States is in excess of $1,500,000,000."}, "enum": {"#tail": "\n        ", "#text": "(7)"}, "@id": "H7451017D2DA84B9183DBDFA3AAC74158", "#text": "\n        "}, {"#tail": "\n    ", "text": {"#tail": " ", "#text": "Annual Federal support for scleroderma research at the National Institutes of Health is currently estimated at $20,000,000."}, "enum": {"#tail": "\n        ", "#text": "(8)"}, "@id": "H2BBF7CB357F04541B785E7BA594C2B27", "#text": "\n        "}], "#text": "\n      ", "@id": "HE5095A7CDD3D494C9E00FBF24EEAE6E8"}, {"#tail": "\n", "enum": {"#tail": "\n      ", "#text": "3."}, "header": {"#tail": " \n", "#text": "National institute of arthritis and musculoskeletal and skin diseases; scleroderma research expansion"}, "subsection": [{"#tail": "\n", "text": {"#tail": " \n", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " shall expand, intensify, and coordinate the activities of the ", "@entity-parent-id": "7529", "@entity-type": "federal-body", "#text": "Director of The National Institute of Arthritis and Musculoskeletal and Skin Diseases", "@value": "National Institute of Arthritis and Musculoskeletal and Skin Diseases"}, {"#tail": " with respect to scleroderma, with particular emphasis on the following areas:", "@entity-parent-id": "7529", "@entity-type": "federal-body", "#text": "Institute", "@value": "National Institute of Arthritis and Musculoskeletal and Skin Diseases"}], "#text": "The "}, "enum": {"#tail": "\n        ", "#text": "(a)"}, "header": {"#tail": "\n        ", "#text": "In general"}, "paragraph": [{"#tail": "\n", "text": {"#tail": " ", "#text": "Research focused on the etiology of scleroderma and the development of new treatment options."}, "enum": {"#tail": "\n          ", "#text": "(1)"}, "@id": "H8B443044906D47C7B8B859E1B992B84", "#text": "\n          "}, {"#tail": "\n", "text": {"#tail": " ", "#text": "Clinical research to evaluate new treatments options."}, "enum": {"#tail": "\n          ", "#text": "(2)"}, "@id": "H30722E46D8BF414A92E5DB3FAEF90DE", "#text": "\n          "}, {"#tail": "\n", "text": {"#tail": " ", "#text": "Basic research on the relationship between scleroderma and secondary conditions such as pulmonary hypertension, gastroparesis, Raynaud\u2019s phenomenon, Sj\u00f6gren\u2019s Syndrome (and other diseases as determined by the Director)."}, "enum": {"#tail": "\n          ", "#text": "(3)"}, "@id": "HC6098E0F8F834364B98EFE15AF777B0", "#text": "\n          "}, {"#tail": "\n", "text": {"#tail": " ", "#text": "Establishment of scleroderma patient registries, including family and childhood onset registries."}, "enum": {"#tail": "\n          ", "#text": "(4)"}, "@id": "H53BAAC63B128448EB77087C7AEBB4DE0", "#text": "\n          "}, {"#tail": "\n      ", "text": {"#tail": " ", "#text": "Support for training of new clinicians and investigators with expertise in scleroderma."}, "enum": {"#tail": "\n          ", "#text": "(5)"}, "@id": "H9A56901C788942C68B11EEC62F00E29C", "#text": "\n          "}], "#text": "\n        ", "@id": "H21DC7D2591F0483C9B9D573931D22FAE"}, {"#tail": "\n", "text": {"#tail": " ", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " shall include information on the status of scleroderma research at the ", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, {"#tail": ".", "@entity-type": "federal-body", "#text": "National Institutes of Health", "@entity-id": "7529"}], "#text": "As a part of the biennial report made under ", "{http://namespaces.cato.org/catoxml}entity": {"#tail": ", the ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " (", "@entity-type": "act", "#text": "section 403 of the Public Health Service Act", "@value": "Public Health Service Act/s:403"}, "@entity-type": "law-citation", "#text": "\n            ", "external-xref": {"#tail": ")", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n            ", "@entity-type": "uscode", "#text": "42 U.S.C. 283", "@value": "usc/42/283"}, "@parsable-cite": "usc/42/283", "#text": "\n              ", "@legal-doc": "usc"}}}, "enum": {"#tail": "\n        ", "#text": "(b)"}, "header": {"#tail": "\n        ", "#text": "Biennial reports"}, "#text": "\n        ", "@id": "H38B66E51AEFF4F80A1FD67698C7900AF"}, {"#tail": "\n    ", "enum": {"#tail": "\n        ", "#text": "(c)"}, "header": {"#tail": " \n", "#text": "Authorization of appropriations"}, "paragraph": [{"#tail": "\n", "text": {"#tail": " ", "#text": "\n            ", "{http://namespaces.cato.org/catoxml}entity": {"#tail": "\n          ", "{http://namespaces.cato.org/catoxml}funds-and-year": [{"#tail": ", ", "#text": "$25,000,000 in fiscal year 2014", "@amount": "25000000", "@year": "2014"}, {"#tail": ", and ", "#text": "$30,000,000 in fiscal year 2015", "@amount": "30000000", "@year": "2015"}, {"#tail": ".", "#text": "$35,000,000 in fiscal year 2016", "@amount": "35000000", "@year": "2016"}], "@entity-type": "auth-auth-approp", "#text": "\n              ", "{http://namespaces.cato.org/catoxml}property": {"#tail": ", there are authorized to be appropriated ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n              ", "@entity-type": "act", "#text": "subsection (a)", "@value": "Scleroderma Research and Awareness Act/s:3/ss:a", "@proposed": "true"}, "#text": "For the purpose of carrying out ", "@name": "purpose"}}}, "enum": {"#tail": "\n          ", "#text": "(1)"}, "header": {"#tail": "\n          ", "#text": "In general"}, "#text": "\n          ", "@id": "H9C85DF7923B34149B2124479D993001"}, {"#tail": "\n      ", "text": {"#tail": " ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": ", not more than 15 percent shall be reserved for the training of qualified health professionals in biomedical research focused on scleroderma.", "@entity-type": "act", "#text": "paragraph (1)", "@value": "Scleroderma Research and Awareness Act/s:3/ss:c/p:1", "@proposed": "true"}, "#text": "Of the amounts authorized to be appropriated under "}, "enum": {"#tail": "\n          ", "#text": "(2)"}, "header": {"#tail": "\n          ", "#text": "Reservations"}, "#text": "\n          ", "@id": "H4258883D02784BACB989FA00E3D1A0BB"}], "#text": "\n        ", "@id": "HB3B9F0F2C9D34036A5B0DD7DDC4F400"}], "#text": "\n      ", "@id": "HCD9864E411244E6FB3CC141D57004983"}, {"#tail": "\n", "enum": {"#tail": "\n      ", "#text": "4."}, "header": {"#tail": " \n", "#text": "Promoting public awareness of scleroderma"}, "subsection": [{"#tail": "\n", "text": {"#tail": " \n", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": ", acting through the ", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, {"#tail": ", shall carry out an educational campaign to increase public awareness of scleroderma. Print, video, and Web-based materials distributed under this program may include\u2014", "@entity-type": "federal-body", "#text": "Director of the Centers for Disease Control and Prevention", "@entity-id": "7523"}], "#text": "The "}, "enum": {"#tail": "\n        ", "#text": "(a)"}, "header": {"#tail": "\n        ", "#text": "In General"}, "paragraph": [{"#tail": "\n", "text": {"#tail": " ", "#text": "basic information on scleroderma and its symptoms;"}, "enum": {"#tail": "\n          ", "#text": "(1)"}, "@id": "H86D02FA87E1948F8A979C0943E372547", "#text": "\n          "}, {"#tail": "\n", "text": {"#tail": " ", "#text": "information on the incidence and prevalence of scleroderma;"}, "enum": {"#tail": "\n          ", "#text": "(2)"}, "@id": "H5DDC964845F544B1B04E7FD16C6988A7", "#text": "\n          "}, {"#tail": "\n", "text": {"#tail": " ", "#text": "diseases and conditions affiliated with scleroderma; or"}, "enum": {"#tail": "\n          ", "#text": "(3)"}, "@id": "H49EE3854893B4181B4ABC51EA6B551B6", "#text": "\n          "}, {"#tail": "\n      ", "text": {"#tail": " ", "#text": "the importance of early diagnosis and treatment."}, "enum": {"#tail": "\n          ", "#text": "(4)"}, "@id": "H2DCCA86E069F4697B7DCD27671D7D8BA", "#text": "\n          "}], "#text": "\n        ", "@id": "H6BFBF563B90A489087C2D19C389E334E"}, {"#tail": "\n", "text": {"#tail": " ", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " is encouraged to disseminate information under ", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, {"#tail": " through a cooperative agreement with a national nonprofit entity with expertise in scleroderma.", "@entity-type": "act", "#text": "subsection (a)", "@value": "Scleroderma Research and Awareness Act/s:4/ss:a", "@proposed": "true"}], "#text": "The "}, "enum": {"#tail": "\n        ", "#text": "(b)"}, "header": {"#tail": "\n        ", "#text": "Dissemination of Information"}, "#text": "\n        ", "@id": "HCCCE0EAECFD14926A8BA7DB47F9F7067"}, {"#tail": "\n", "text": {"#tail": " ", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " shall report to the ", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, {"#tail": " and ", "@entity-type": "committee", "#text": "Committees on Health, Education, Labor, and Pensions", "@entity-id": "SSHR00"}, {"#tail": " and the ", "@entity-type": "committee", "#text": "Appropriations of the Senate", "@entity-id": "SSAP00"}, {"#tail": " and ", "@entity-type": "committee", "#text": "Committees on Energy and Commerce", "@entity-id": "HIF00"}, {"#tail": " on the status of activities under this section.", "@entity-type": "committee", "#text": "Appropriations of the House of Representatives", "@entity-id": "HAP00"}], "#text": "Not later than September 30, 2013, the "}, "enum": {"#tail": "\n        ", "#text": "(c)"}, "header": {"#tail": "\n        ", "#text": "Report to Congress"}, "#text": "\n        ", "@id": "HC2294FF45EFB49F6B861CB30B3E79DFB"}, {"#tail": "\n    ", "text": {"#tail": " ", "#text": "\n          ", "{http://namespaces.cato.org/catoxml}entity": {"#tail": "\n        ", "{http://namespaces.cato.org/catoxml}funds-and-year": {"#tail": ".", "#text": "$2,500,000 for each of fiscal years 2014, 2015, and 2016", "@amount": "2500000", "@year": "2014, 2015, 2016"}, "@entity-type": "auth-auth-approp", "#text": "\n            ", "{http://namespaces.cato.org/catoxml}property": {"#tail": ", there is authorized to be appropriated ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n            ", "@entity-type": "act", "#text": "this section", "@value": "Scleroderma Research and Awareness Act/s:4", "@proposed": "true"}, "#text": "For the purpose of carrying out ", "@name": "purpose"}}}, "enum": {"#tail": "\n        ", "#text": "(d)"}, "header": {"#tail": "\n        ", "#text": "Authorization of Appropriations"}, "#text": "\n        ", "@id": "H68266477FA874C4B9251A600B24E06BD"}], "#text": "\n      ", "@id": "H0ED8B5154E8B438E81DD087FDD44E474"}], "#text": " \n"}, "metadata": {"#tail": "\n", "dublinCore": {"{http://purl.org/dc/elements/1.1/}date": {"#tail": "\n", "#text": "2013-06-27"}, "{http://purl.org/dc/elements/1.1/}format": {"#tail": "\n", "#text": "text/xml"}, "{http://purl.org/dc/elements/1.1/}language": {"#tail": "\n", "#text": "EN"}, "#tail": "\n", "{http://purl.org/dc/elements/1.1/}title": {"#tail": "\n", "#text": "113 S1239 IS: Scleroderma Research and Awareness Act"}, "{http://purl.org/dc/elements/1.1/}rights": {"#tail": "\n", "#text": "Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain."}, "{http://purl.org/dc/elements/1.1/}publisher": {"#tail": "\n", "#text": "U.S. Senate"}, "#text": "\n"}, "#text": "\n"}}}